A Trial to Test the Safety and Efficacy of TEV-53408 in Participants With Vitiligo
Public ClinicalTrials.gov record NCT06625177. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1b, Open-Label Trial to Assess Safety and Exploratory Efficacy of TEV-53408 in Participants With Vitiligo
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of the trial is to evaluate the safety of TEV-53408 when given as an under the skin injection to adults with vitiligo. Vitiligo is a condition where patches of skin lose color (pigment) and turn white.
Study identification
- NCT ID
- NCT06625177
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 66 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 18 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 10, 2024
- Primary completion
- Apr 25, 2028
- Completion
- Jan 30, 2029
- Last update posted
- Aug 31, 2026
2024 – 2029
United States locations
- U.S. sites
- 13
- U.S. states
- 10
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Teva Investigational Site 12043 | Scottsdale | Arizona | 85260 | — |
| Teva Investigational Site 12052 | Hot Springs | Arkansas | 71913 | — |
| Teva Investigational Site 12044 | Fremont | California | 94538 | — |
| Teva Investigational Site 12051 | Irvine | California | 92617 | — |
| Teva Investigational Site 12046 | Pasadena | California | 91101 | — |
| Teva Investigational Site 12049 | Miramar | Florida | 33025 | — |
| Teva Investigational Site 12047 | Chicago | Illinois | 60614 | — |
| Teva Investigational Site 12053 | Louisville | Kentucky | 40421 | — |
| Teva Investigational Site 12048 | Canton | Michigan | 48187 | — |
| Teva Investigational Site 12054 | Portland | Oregon | 97210 | — |
| Teva Investigational Site 12045 | Dallas | Texas | 75230 | — |
| Teva Investigational Site 12057 | Webster | Texas | 77598 | — |
| Teva Investigational Site 12055 | South Jordan | Utah | 84095 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06625177, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 31, 2026 · Synced Sep 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06625177 live on ClinicalTrials.gov.